6 months ago
GILD
AnalystsBrian AbrahamsBrian Abrahams's Stock Forecasts
AnalystsBrian Abrahams
Analyst Ranking
Top 15%
#761 out of 5186 analysts
Average Return
+3.87%
Win Rate
45%134 out of 298
Risk vs Reward
Poor
Good
Brian Abrahams's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
89bio IncETNB | +558.80% | $2.67 | $17.59 | 2022-05-11 - 2023-05-11 | Buy |
Pliant Therapeutics IncPLRX | +382.01% | $4.67 | $22.51 | 2022-05-09 - 2023-05-09 | Buy |
Cidara Therapeutics IncCDTX | +372.63% | $46.84 | $221.38 | 2025-06-23 - 2026-01-06 | Buy |
Contineum Therapeutics IncCTNM | +280.71% | $3.94 | $15.00 | 2025-05-14 - 2026-02-06 | Buy |
Ambrx Biopharma IncAMAM | +233.33% | $8.40 | $28.00 | 2023-10-22 - 2024-03-06 | Buy |
Brian Abrahams Analyst Color
Get additional color on Brian Abrahams's coverage of popular stocks
a year ago
APLT
2 years ago
DFTX
Brian Abrahams's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Acadia Pharmaceuticals IncACAD | 4 | Buy | $31.00 | +31.58% | Maintains | 6 days ago |
Biocryst Pharmaceuticals IncBCRX | 16 | Buy | $13.00 | +103.76% | Maintains | 10 days ago |
Nurix Therapeutics IncNRIX | 1 | Buy | $30.00 | +78.04% | Maintains | 11 days ago |
Gh Research PLCGHRS | 2 | Buy | $40.00 | +163.77% | Maintains | 17 days ago |
Definium Therapeutics IncDFTX | 11 | Buy | $36.00 | +113.02% | Maintains | 17 days ago |
Vertex Pharmaceuticals IncVRTX | 56 | Buy | $546.00 | +14.25% | Upgrades | 18 days ago |
Apogee Therapeutics IncAPGE | 3 | Hold | $83.00 | +33.35% | Downgrades | 18 days ago |
Kymera Therapeutics IncKYMR | 2 | Buy | $103.00 | +29.41% | Maintains | 2 months ago |
Neurocrine Biosciences IncNBIX | 23 | Buy | $180.00 | +27.48% | Maintains | 2 months ago |
Sionna Therapeutics IncSION | 2 | Sell | $24.00 | -33.54% | Downgrades | 2 months ago |
Ptc Therapeutics IncPTCT | 19 | Hold | $91.00 | +21.85% | Downgrades | 2 months ago |
Neumora Therapeutics IncNMRA | 7 | Buy | $7.00 | +230.19% | Upgrades | 2 months ago |
Contineum Therapeutics IncCTNM | 6 | Buy | $22.00 | +46.67% | Maintains | 3 months ago |
Aardvark Therapeutics IncAARD | 5 | Buy | $18.00 | +42.29% | Maintains | 3 months ago |
Corbus Pharmaceuticals Holdings IncCRBP | 8 | Buy | $53.00 | +576.88% | Maintains | 3 months ago |
Atyr Pharma IncATYR | 2 | Hold | $1.00 | +11.23% | Maintains | 3 months ago |
Prothena Corp Public Ltd CoPRTA | 12 | Hold | $11.00 | +23.46% | Maintains | 3 months ago |
Pliant Therapeutics IncPLRX | 14 | Hold | $2.00 | +75.44% | Maintains | 3 months ago |
Galapagos NvGLPG | 12 | Hold | $32.00 | -4.08% | Maintains | 3 months ago |
Cidara Therapeutics IncCDTX | 2 | Buy | $145.00 | -34.50% | Maintains | 3 months ago |
Xenon Pharmaceuticals IncXENE | 20 | Buy | $58.00 | +40.16% | Maintains | 3 months ago |
Karyopharm Therapeutics IncKPTI | 12 | Buy | $19.00 | +203.51% | Maintains | 3 months ago |
Gilead Sciences IncGILD | 32 | Hold | $105.00 | -31.15% | Maintains | 3 months ago |
Biogen IncBIIB | 39 | Buy | $210.00 | +4.38% | Maintains | 3 months ago |
Regeneron Pharmaceuticals IncREGN | 35 | Hold | $708.00 | -9.87% | Maintains | 3 months ago |
Incyte CorpINCY | 23 | Hold | $84.00 | -22.50% | Maintains | 3 months ago |
Moonlake ImmunotherapeuticsMLTX | 3 | Hold | $10.00 | -35.53% | Downgrades | 4 months ago |
89bio IncETNB | 14 | Hold | $11.00 | -25.88% | Maintains | 6 months ago |
Sarepta Therapeutics IncSRPT | 31 | Hold | $23.00 | +24.32% | Maintains | 7 months ago |
Applied Therapeutics IncAPLT | 6 | Hold | $1.50 | +1,356.31% | Reiterates | 9 months ago |
Legend Biotech CorpLEGN | 1 | Buy | $84.00 | +391.23% | Reiterates | 10 months ago |
Axsome Therapeutics IncAXSM | 2 | Buy | $143.00 | N/A | Maintains | a year ago |
Newamsterdam Pharma Co NvNAMS | 1 | Buy | $40.00 | N/A | Reiterates | a year ago |
Intra Cellular Therapies IncITCI | 18 | Hold | $132.00 | N/A | Downgrades | a year ago |
Igm Biosciences IncIGMS | 15 | Hold | $1.50 | N/A | Downgrades | a year ago |
Hookipa Pharma IncHOOK | 11 | Hold | $2.00 | N/A | Downgrades | a year ago |
Sage Therapeutics IncSAGE | 19 | Hold | $4.00 | N/A | Upgrades | a year ago |
Marinus Pharmaceuticals IncMRNS | 8 | Hold | $1.00 | N/A | Maintains | a year ago |
Ambrx Biopharma IncAMAM | 3 | Buy | $32.00 | N/A | Maintains | 2 years ago |
Karuna Therapeutics IncKRTX | 7 | Buy | $225.00 | N/A | Maintains | 2 years ago |
Enanta Pharmaceuticals IncENTA | 14 | Hold | $15.00 | N/A | Maintains | 2 years ago |
Intercept Pharmaceuticals IncICPT | 11 | Hold | $19.00 | N/A | Maintains | 2 years ago |
Atai Beckley NvATAI | 3 | Hold | $9.00 | N/A | Maintains | 4 years ago |
Merus NvMRUS | 3 | Hold | $33.00 | N/A | Maintains | 4 years ago |
Constellation Pharmaceuticals IncCNST | 1 | Hold | $34.00 | N/A | Downgrades | 5 years ago |
Metacrine IncMTCR | 1 | Buy | $25.00 | N/A | Initiates Coverage On | 5 years ago |
Neubase Therapeutics IncNBSE | 1 | Buy | $320.00 | N/A | Initiates Coverage On | 6 years ago |
Celgene CorpCELG | 2 | Buy | $118.00 | N/A | Downgrades | 8 years ago |
Ultragenyx Pharmaceutical IncRARE | 2 | Strong Buy | N/A | N/A | Upgrades | 8 years ago |
Epizyme IncEPZM | 1 | Hold | N/A | N/A | Downgrades | 8 years ago |
Alder Biopharmaceuticals IncALDR | 1 | Buy | $17.00 | N/A | Initiates Coverage On | 8 years ago |
Immune Design CorpIMDZ | 1 | Buy | $20.00 | N/A | Initiates Coverage On | 8 years ago |
Avexis IncAVXS | 1 | Hold | $92.00 | N/A | Initiates Coverage On | 8 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.